⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406386 | 0.90 | — | — | |
| SCHEMBL8012146 | 0.90 | — | — | |
| SCHEMBL8614213 | 0.90 | — | — | |
| SCHEMBL10799532 | 0.90 | — | — | |
| Zinc Ion SCHEMBL10795152 | 0.90 | — | — | |
| Potassium Ion SCHEMBL14936086 | 0.90 | — | — | |
| Potassium Ion SCHEMBL16447243 | 0.90 | — | — | |
| SCHEMBL15330242 | 0.90 | — | — | |
| SCHEMBL11878059 | 0.90 | — | — | |
| Potassium Ion SCHEMBL21383840 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| US-11871772-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023244672-A1 | 2-(IMIDAZO[1, 2-A]1,8-NAPHTHYRIDIN-8-YL)-1,3,4-OXADIAZOLE DERIVATIVES AS ENHANCERS OF INNATE IMMUNE RESPONSE FOR THE TREATMENT OF VIRAL INFECTIONS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3672975-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | Newave Pharmaceutical Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190109-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019040550-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180140600-A1 | DEUTERATED DEHYDROPHENYLAHISTIN COMPOUNDS AND PREPARATION METHOD THEREOF AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUGS | SHENZHEN HUAHONG MARINE BIOMEDICINE CO., LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |